Top Markets
Coin of the day
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.

Taisho Pharmaceutical Holdings Co., Ltd.

4581
Rangering i aksjer #3839
Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise... Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise involved in the comprehensive research, development, production, marketing, and distribution of both non-prescription (OTC) and ethical pharmaceutical products, serving markets in Japan and worldwide. The company's operations are divided into two principal divisions: the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group. The Self-Medication Group provides a diverse portfolio of consumer health products, including over-the-counter medicines, quasi-pharmaceuticals, food products, and general medical and hygiene items. Prominent brands within this segment include the Lipovitan energy drink series, Pabron cold and sinus remedies, RiUP hair re-growth solutions, Taisho Kampo gastrointestinal treatments, Colac laxatives, Naron and other pain relievers for fever, Preser hemorrhoid treatments, Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic-analgesic relief, Counterpain topical anti-inflammatory products, Vitacilina dermatological treatments, and VICKS cough suppressant throat lozenges and medicated drops. This division also encompasses real estate leasing, facility management, and hotel operations. Conversely, the Prescription Pharmaceutical Group specializes in ethical drugs such as Edirol, an active vitamin D3 agent for osteoporosis; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate for osteoporosis; Lusefi, an agent for type 2 diabetes mellitus; and LOQOA, a transdermal anti-inflammatory analgesic. This segment is also engaged in ongoing drug development, primarily focusing on therapeutic areas like central nervous system disorders, infectious diseases, metabolic conditions, and orthopedic ailments. Additionally, Taisho Pharmaceutical Holdings supplies raw materials for pharmaceutical and quasi-drug manufacturing, alongside offering health foods and skincare products. The company was established in Tokyo, Japan, in 1912, where its headquarters remain.
Aksjekurs
$55.98
Sist synkronisert: 2024-04-08
Markedsverdi
$4.59B
Endring (1 dag)
-1.20%
Endring (1 år)
0.00%
Land
JP
Handel Taisho Pharmaceutical Holdings Co., Ltd. (4581)

Kategori

Pris 4581 pris med markedsverdi på B
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
4581
$55.98
Markedsverdi av Taisho Pharmaceutical Holdings Co., Ltd.(4581)
Markedsverdi: $4.59B
Per August 2026 har Taisho Pharmaceutical Holdings Co., Ltd. en markedsverdi på $4.59B. Dette gjør Taisho Pharmaceutical Holdings Co., Ltd. til det 3839th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Taisho Pharmaceutical Holdings Co., Ltd. fra 2011 til 2026
4581 sammenlignet med topp 5 mest populære stocks
Pris på 4581 Eiendel B Markedsverdi for B Resultater
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
$62,860.00 $4.59B
$5.152T +112,191.92%
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
$55,351.35 $4.59B
$4.537T +98,778.61%
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
$50,856.25 $4.59B
$4.169T +90,748.65%
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
$44,436.43 $4.59B
$3.642T +79,280.41%
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
$34,217.20 $4.59B
$2.805T +61,024.96%